Literature DB >> 16823383

Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice.

Jakub Fichna1, Anna Janecka, Mariola Piestrzeniewicz, Jean Costentin, Jean-Claude do Rego.   

Abstract

Endomorphin-1 (Tyr-Pro-Trp-Phe-NH(2)) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH(2)) are two recently isolated mu-opioid selective peptides with a potent antinociceptive activity, involved in a number of physiological processes, including food intake, vasomotricity, sexual behavior, as well as neuroendocrine and cardiorespiratory functions. The neuroanatomical distribution of endomorphins prompted us to study their antidepressant activity in two animal behavioral models of depression: forced-swimming and tail-suspension tests. In both tests, the intracerebroventricular (i.c.v.) injection of either endomorphin-1 or endomorphin-2 significantly decreased the duration of immobility, interpreted as an expression of 'behavioral despair', which could be related to the depression syndrome. These effects of endomorphins did not result from the stimulation of the animal motor activity. We have also demonstrated that the antidepressant-like effect of endomorphins was antagonized by the universal opioid antagonist, naloxone and the mu-opioid receptor selective antagonist, beta-funaltrexamine. In contrast, this effect was not antagonized by delta- and kappa-opioid receptor selective antagonists, naltrindole and nor-binaltorphimine, respectively. The results of the present study demonstrate that endomorphin-1 and endomorphin-2 produce potent antidepressant-like effects after i.c.v. injection in mice. We may suggest that endomorphins and the mu-opioid receptors might be involved in the physiopathology of depressive disorders, and that the endomorphinergic system could serve as a novel target for the development of antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823383     DOI: 10.1038/sj.npp.1301149

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  8 in total

1.  Mapping of reinforcing and analgesic effects of the mu opioid agonist endomorphin-1 in the ventral midbrain of the rat.

Authors:  Thomas C Jhou; Sheng-Ping Xu; Mary R Lee; Courtney L Gallen; Satoshi Ikemoto
Journal:  Psychopharmacology (Berl)       Date:  2012-06-06       Impact factor: 4.530

Review 2.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

3.  Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.

Authors:  Abdulrahman Almatroudi; Stephen M Husbands; Christopher P Bailey; Sarah J Bailey
Journal:  J Psychopharmacol       Date:  2015-06-04       Impact factor: 4.153

4.  Antidepressant-like effect of venlafaxine is abolished in μ-opioid receptor-knockout mice.

Authors:  Soichiro Ide; Shunsuke Fujiwara; Masayuki Fujiwara; Ichiro Sora; Kazutaka Ikeda; Masabumi Minami; George R Uhl; Kumatoshi Ishihara
Journal:  J Pharmacol Sci       Date:  2010-08-10       Impact factor: 3.337

5.  Reduced emotional and corticosterone responses to stress in mu-opioid receptor knockout mice.

Authors:  Soichiro Ide; Ichiro Sora; Kazutaka Ikeda; Masabumi Minami; George R Uhl; Kumatoshi Ishihara
Journal:  Neuropharmacology       Date:  2009-07-14       Impact factor: 5.250

6.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.

Authors:  Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2016-05-18       Impact factor: 15.419

7.  The Association Between Midlife Physical Activity and Depressive Symptoms in Late Life: Age Gene/Environment Susceptibility-Reykjavik Study.

Authors:  Milan Chang; Jon Snaedal; Bjorn Einarsson; Sigurbjorn Bjornsson; Jane S Saczynski; Thor Aspelund; Melissa Garcia; Vilmundur Gudnason; Tamara B Harris; Lenore J Launer; Palmi V Jonsson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-11-02       Impact factor: 6.053

8.  Prospective investigation of intravenous patient-controlled analgesia with hydromorphone or sufentanil: impact on mood, opioid adverse effects, and recovery.

Authors:  Yanqing Yang; Jianping Wu; Huiling Li; Sujuan Ye; Xiaoying Xu; Ling Cheng; Lina Zhu; Zhiyou Peng; Zhiying Feng
Journal:  BMC Anesthesiol       Date:  2018-04-10       Impact factor: 2.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.